These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 25416980)
1. Possible role of resveratrol targeting estradiol and neprilysin pathways in lipopolysaccharide model of Alzheimer disease. El-Sayed NS; Bayan Y Adv Exp Med Biol; 2015; 822():107-18. PubMed ID: 25416980 [TBL] [Abstract][Full Text] [Related]
2. Recombinant soluble neprilysin reduces amyloid-beta accumulation and improves memory impairment in Alzheimer's disease mice. Park MH; Lee JK; Choi S; Ahn J; Jin HK; Park JS; Bae JS Brain Res; 2013 Sep; 1529():113-24. PubMed ID: 23831521 [TBL] [Abstract][Full Text] [Related]
3. Effect of Tong Luo Jiu Nao on Aβ-degrading enzymes in AD rat brains. Liu Y; Hua Q; Lei H; Li P J Ethnopharmacol; 2011 Sep; 137(2):1035-46. PubMed ID: 21798326 [TBL] [Abstract][Full Text] [Related]
4. [Effects of Naoerkang on expressions of beta-amyloid peptide 1-42 and neprilysin in hippocampus in a rat model of Alzheimer's disease]. Yuan HF; Li X; Quan QK; Wang NN; Li Y; Li M Zhong Xi Yi Jie He Xue Bao; 2010 Feb; 8(2):152-7. PubMed ID: 20141738 [TBL] [Abstract][Full Text] [Related]
5. Aβ-degrading enzymes: potential for treatment of Alzheimer disease. Miners JS; Barua N; Kehoe PG; Gill S; Love S J Neuropathol Exp Neurol; 2011 Nov; 70(11):944-59. PubMed ID: 22002425 [TBL] [Abstract][Full Text] [Related]
6. Blood-brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer's disease. Rofo F; Metzendorf NG; Saubi C; Suominen L; Godec A; Sehlin D; Syvänen S; Hultqvist G Alzheimers Res Ther; 2022 Dec; 14(1):180. PubMed ID: 36471433 [TBL] [Abstract][Full Text] [Related]
7. Activating AhR alleviates cognitive deficits of Alzheimer's disease model mice by upregulating endogenous Aβ catabolic enzyme Neprilysin. Qian C; Yang C; Lu M; Bao J; Shen H; Deng B; Li S; Li W; Zhang M; Cao C Theranostics; 2021; 11(18):8797-8812. PubMed ID: 34522212 [No Abstract] [Full Text] [Related]
8. Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications. Jha NK; Jha SK; Kumar D; Kejriwal N; Sharma R; Ambasta RK; Kumar P J Alzheimers Dis; 2015; 48(4):891-917. PubMed ID: 26444774 [TBL] [Abstract][Full Text] [Related]
9. Simvastatin and atorvastatin facilitates amyloid β-protein degradation in extracellular spaces by increasing neprilysin secretion from astrocytes through activation of MAPK/Erk1/2 pathways. Yamamoto N; Fujii Y; Kasahara R; Tanida M; Ohora K; Ono Y; Suzuki K; Sobue K Glia; 2016 Jun; 64(6):952-62. PubMed ID: 26875818 [TBL] [Abstract][Full Text] [Related]
10. 5-HIAA induces neprilysin to ameliorate pathophysiology and symptoms in a mouse model for Alzheimer's disease. Klein C; Roussel G; Brun S; Rusu C; Patte-Mensah C; Maitre M; Mensah-Nyagan AG Acta Neuropathol Commun; 2018 Dec; 6(1):136. PubMed ID: 30537985 [TBL] [Abstract][Full Text] [Related]
11. Insulin-signaling Pathway Regulates the Degradation of Amyloid β-protein via Astrocytes. Yamamoto N; Ishikuro R; Tanida M; Suzuki K; Ikeda-Matsuo Y; Sobue K Neuroscience; 2018 Aug; 385():227-236. PubMed ID: 29932983 [TBL] [Abstract][Full Text] [Related]
12. Anti-amyloid activity of neprilysin in plaque-bearing mouse models of Alzheimer's disease. Mohajeri MH; Kuehnle K; Li H; Poirier R; Tracy J; Nitsch RM FEBS Lett; 2004 Mar; 562(1-3):16-21. PubMed ID: 15043995 [TBL] [Abstract][Full Text] [Related]
13. Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective. Ali NH; Al-Kuraishy HM; Al-Gareeb AI; Alnaaim SA; Alexiou A; Papadakis M; Khalifa AA; Saad HM; Batiha GE J Cell Mol Med; 2024 Jan; 28(2):e17993. PubMed ID: 37847125 [TBL] [Abstract][Full Text] [Related]
14. Messenger RNA-based therapeutics for brain diseases: An animal study for augmenting clearance of beta-amyloid by intracerebral administration of neprilysin mRNA loaded in polyplex nanomicelles. Lin CY; Perche F; Ikegami M; Uchida S; Kataoka K; Itaka K J Control Release; 2016 Aug; 235():268-275. PubMed ID: 27282413 [TBL] [Abstract][Full Text] [Related]
16. Neprilysin degrades murine Amyloid-β (Aβ) more efficiently than human Aβ: Further implication for species-specific amyloid accumulation. Becker M; Moore A; Naughton M; Boland B; Siems WE; Walther T Neurosci Lett; 2018 Nov; 686():74-79. PubMed ID: 30144539 [TBL] [Abstract][Full Text] [Related]
17. Self-assembling nanofibers alter the processing of amyloid precursor protein in a transgenic mouse model of Alzheimer's disease. Yang H; Yang H; Xie Z; Wang P; Bi J Neurol Res; 2015 Jan; 37(1):84-91. PubMed ID: 25005263 [TBL] [Abstract][Full Text] [Related]
18. Epigallocatechin gallate induces extracellular degradation of amyloid β-protein by increasing neprilysin secretion from astrocytes through activation of ERK and PI3K pathways. Yamamoto N; Shibata M; Ishikuro R; Tanida M; Taniguchi Y; Ikeda-Matsuo Y; Sobue K Neuroscience; 2017 Oct; 362():70-78. PubMed ID: 28844000 [TBL] [Abstract][Full Text] [Related]
19. Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. Wang DS; Lipton RB; Katz MJ; Davies P; Buschke H; Kuslansky G; Verghese J; Younkin SG; Eckman C; Dickson DW J Neuropathol Exp Neurol; 2005 May; 64(5):378-85. PubMed ID: 15892294 [TBL] [Abstract][Full Text] [Related]
20. Oxidized neprilysin in aging and Alzheimer's disease brains. Wang DS; Iwata N; Hama E; Saido TC; Dickson DW Biochem Biophys Res Commun; 2003 Oct; 310(1):236-41. PubMed ID: 14511676 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]